RE: De risk/strategy8 Jan 2023 11:54
I don’t have a selling strategy and I won’t set one until I know whether Hemogenyx have been awarded the bio-defense grant at the end of March. Because if they are, it’s highly likely that CBR will have been proven to work in combating at least three live viruses. Also Hemogenyx will, in my opinion, be a clinical company with the first patients having started HEMO CAR-T therapy. I am also pretty sure that Hemogenyx will have made a major announcement on their CDX bi-specific antibody. So in the next twelve weeks, once I know the full potential of the company I’ll decide what to do. Balancing risk versus reward I think is relatively easy for this stock as I’ve always believed that CAR-T alone will put every holder in profit, even those who were severely spiked a few years ago. If CAR-T is the cake, then CDX is the icing and CBR is very much the cherry on top. What you eat and when you eat it is very much a personal choice. The only advice I’d give anyone today is don’t be too greedy. GLA